Seelos therapeutics announces interim data from phase i study of intranasal racemic ketamine

Seelos therapeutics announces interim data from phase i study of intranasal racemic ketamine (sls-002).seelos therapeutics inc - additional data from ongoing phase i studies of sls-002 expected throughout q1 of 2020.seelos therapeutics - data from study sls-002-101 demonstrated that 60mg of sls-002 was generally safe and well-tolerated.seelos therapeutics - one of 42 subjects discontinued sls-002 trial prematurely.
SEEL Ratings Summary
SEEL Quant Ranking